Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023
Shots:
- The P-III trial evaluating the efficacy, safety, PK & immunogenicity of nemolizumab vs PBO in adult patients with mod. to sev. PN
- The study met all 1EPs & 2EPs i.e., 19.7% of patients treated with nemolizumab monotx. achieved an itch-free state as early as 4wk. after 1 dose of nemolizumab, 100% of adults reported intense itching with PP-NRS reduction ≥ 4 points (41.0% vs 7.7%), improvement in sleep intensity & skin clearance, rapid onset of action was also highlighted. The safety profile was consistent with the P-II study results
- The (OLYMPIA 2) study results also presented at AAD showed that nearly 4 times as many patients achieved an improvement in sleep disturbance as measured by a 4-point improvement on SD-NRS (37.2% vs 9.9%)
Ref: Businesswire | Image: Galderma
Related News:- Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
